ImmunoPrecise Antibodies Ltd. has released a presentation highlighting their advancements in therapeutic workflows and antibody discovery. The presentation details their use of AI-driven technologies for early-stage insights, high-throughput screening, and data-driven decision making to accelerate timelines in antibody development. Key features include the integration of the LENSai platform for target analysis, epitope prediction, and lead optimization processes. The potential of rabbit-derived antibodies for therapeutic and diagnostic applications is also discussed, emphasizing their high affinity and specificity. You can access the full presentation through the link below.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。